Reem Al-Saadi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2785731/publications.pdf

Version: 2024-02-01

19	775	11	19
papers	citations	h-index	g-index
19	19	19	1487
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Surgical management, staging, and outcomes of Wilms tumours with intravascular extension: Results of the IMPORT study. Journal of Pediatric Surgery, 2022, 57, 572-578.	1.6	7
2	Long-term kidney function in children with Wilms tumour and constitutional WT1 pathogenic variant. Pediatric Nephrology, 2022, 37, 821-832.	1.7	5
3	Characteristics and outcomes of preoperatively treated patients with anaplastic Wilms tumors registered in the UK SIOPâ€WTâ€2001 and IMPORT study cohorts (2002â€2020). Cancer, 2022, 128, 1666-1675	5.4.1	6
4	Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only â^ the SIOP 93–01 and 2001 protocols. European Journal of Cancer, 2022, 163, 88-97.	2.8	8
5	Outcome of Stage IV Completely Necrotic Wilms Tumour and Local Stage III Treated According to the SIOP 2001 Protocol. Cancers, 2021, 13, 976.	3.7	6
6	Characteristics and outcome of pediatric renal cell carcinoma patients registered in the International Society of Pediatric Oncology (<scp>SIOP</scp>) 93â€01, 2001 and <scp>UKâ€IMPORT</scp> database: A report of the <scp>SIOPâ€Renal</scp> Tumor Study Group. International Journal of Cancer, 2021, 148, 2724-2735.	5.1	26
7	Comparative analysis of the clinical characteristics and outcomes of patients with Wilms tumor in the United Kingdom and Japan. Pediatric Blood and Cancer, 2021, 68, e29143.	1.5	7
8	Prognostic significance of histopathological response to preoperative chemotherapy in unilateral Wilms' tumor: An analysis of 899 patients treated on the SIOP WT 2001 protocol in the UKâ€CCLG and GPOH studies. International Journal of Cancer, 2021, 149, 1332-1340.	5.1	16
9	Setting international standards for patient and parent involvement and engagement in childhood, adolescent and young adult cancer research: A report from a European Collaborative Workshop. Cancer Reports, 2021, , e1523.	1.4	7
10	An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nature Communications, 2020, 11 , 1310 .	12.8	183
11	Somatic TP53 Mutations Are Detectable in Circulating Tumor DNA from Children with Anaplastic Wilms Tumors. Translational Oncology, 2018, 11, 1301-1306.	3.7	21
12	Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials. Pediatric Blood and Cancer, 2017, 64, e26386.	1.5	21
13	Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma. Clinical Cancer Research, 2016, 22, 1265-1273.	7.0	23
14	Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. Nature Communications, 2015, 6, 5973.	12.8	161
15	Prediction of relapse in stage I nonseminomatous germ cell tumors (NSGCT) by CXCL12: Results from the MRC TE08 and TE22 clinical trials Journal of Clinical Oncology, 2013, 31, 319-319.	1.6	4
16	Stratification of Wilms tumor by genetic and epigenetic analysis. Oncotarget, 2012, 3, 327-335.	1.8	101
17	Molecular profiling reveals frequent gain of <i>MYCN</i> and anaplasiaâ€specific loss of 4q and 14q in wilms tumor. Genes Chromosomes and Cancer, 2011, 50, 982-995.	2.8	54
18	Subtype-Specific <i>FBXW7</i> Mutation and <i>MYCN</i> Copy Number Gain in Wilms' Tumor. Clinical Cancer Research, 2010, 16, 2036-2045.	7.0	69

#	ARTICLE	IF	CITATIONS
19	Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1–3 clinical trials: A Children's Cancer and Leukaemia Group (CCLG) study. European Journal of Cancer, 2009, 45, 819-826.	2.8	50